Table 1.
Clinical studies investigating target therapies in ACC
| Target therapy (reference) | Target | Study phase | Number of patients | Response | Median survival |
|---|---|---|---|---|---|
| Sunitinib [16] | VEGFR, RET, RET/PTC | II | 38 | SD 5/38 PD 24/38 6 deaths prior to evaluation | PFS 2.8 months |
| Axitinib [17] | VEGFR | II | 13 | SD 8/13 (>3 months) | PFS 5.8 months |
| Sorafenib + paclitaxel [13] | VEGFR, RET, BRAF | II | 10 | PD 90 % | NR |
| Cixutumumab + temsirolimus [19] | IGF1R + mTOR | I | 26 | SD 42 % (>6 months) | TTP 9 months |
| Cixutumumab + mitotane [20] | IGF1R | II | 20 |
PR 5 % SD 35 % |
PFS 1.5 months |
| Linsitinib [21] | IGF-1R | III | 139 (90 linsitinib/ 49 placebo) |
PR 3 % SD 6.7 % (>6 months) |
PFS 44 days linsitinib vs 46 days placebo |
Abbreviations: PR partial response, SD stable disease, PD progressive disease, PFS progression-free survival, TTP time to progression